Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Classic Gathering Of shares

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Mar 18, 2021 10:42am

189 Views

Post# 32825424

RE:RE:Classic Gathering Of shares

Pretty red day today but ATE is up. On ant deal someone always gets a tip from who knows who but they will be buying well before the NR. It might be a week or so early but they know it's coming.
They don't want to run it up to fast but just enough and over a few days they gather many shares.
Time will tell if I'm right? I would not sell into this, as Dan says it could be any day that a deal is struck.

<< Previous

Bullboard Posts

Next >>

Canada Nickel unveils second of seven resources planned by mid-2025